Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a classic glycolytic enzyme, and accumulating evidence has suggested that GAPDH is a multi-functional protein. In particular, its role as a mediator for cell death has been highlighted. For the last decade, many groups reported that a pool of GAPDH translocates to the nucleus under a variety of stressors, most of which are associated with oxidative stress. At the molecular level, sequential steps lead to nuclear translocation of GAPDH during cell death as follows: first, a catalytic cysteine in GAPDH (C150 in rat GAPDH) is S-nitrosylated by nitric oxide (NO) that is generated from inducible nitric oxide synthase (iNOS) and/or neuronal NOS (nNOS); second, the modified GAPDH becomes capable of binding with Siah1, an E3 ubiquitin ligase, and stabilizes it; third, the GAPDH-Siah protein complex translocates to the nucleus, dependent on Siah1's nuclear localization signal, and degrades Siah1's substrates in the nucleus, which results in cytotoxicity. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease. (−)-deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions, but its molecular mechanism is still unclear. The NO/GAPDH/ Siah1 death cascade will contribute to the molecular understanding of a role of GAPDH in neurodegenerative disorders and help to establish novel therapeutic strategies.
GAPDH: more than a housekeeping glycolytic enzyme
For many decades, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been regarded merely as a housekeeping glycolytic enzyme that exists mainly in the cytoplasm. However, a variety of recent studies are now suggesting that GAPDH is a multifunctional protein [1, 2] . GAPDH binds to microtubules and modulates microtubule bundling [3] [4] [5] , and also contributes to membrane fusion [6, 7] . Gross and colleagues [8] proposed a scheme whereby an isoform of GAPDH, recruited by GTP-activated Rab to vesicles associated with microtubules, is sequentially phosphorylated by protein kinase C and catalyzes membrane fusion [9, 10] . GAPDH also binds to the inositol 1,4,5-trisphosphate receptor (IP3R), modulating calcium flux [11] .
GAPDH exists in the nucleus and plays a role in gene transcription, DNA replication, DNA repair, and nuclear RNA export [12] [13] [14] [15] . Sirover and colleagues revealed that GAPDH functions as a uracil DNA glycosylase (UDG), involved in DNA repair mechanisms [14] . UDGs repair uracils in DNA caused by cytosine deamination. GAPDH is found in the nucleus of human cells in a cell-cycle dependent manner [16] , and has been identified as a necessary component for the proper functioning of an Oct-1 coactivator, OCA-S, that is essential for S phase-dependent histone H2B transcription in HeLa cells [15] . Consistent with this, GAPDH was isolated as a singlestranded DNA-biding protein, which is a possible activator of transcription in neurons [12] . It has also been found that nuclear GAPDH associates with telomeric DNA and plays a functional role in maintenance of telomeres [17] .
In addition to the various functions of GAPDH described above, recent studies have clarified a role for this molecule during cell death, frequently associated with oxidative stress [2, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Furthermore, GAPDH binds to several proteins that are responsible for neurodegenerative diseases, such as amyloid precursor protein and Huntingtin [34, 35] , but the role of GAPDH in these protein interactions is still unclear. The present mini-review focuses the roles of GAPDH in pathological conditions, especially cell death triggered by nitric oxide (NO).
GAPDH and Nitric oxide (NO)
NO is one of the major cellular signaling molecules and is known to mediate cell death. Initially it was shown that NO causes necrotic cell death via a formation of peroxynitrite, a powerful oxidant that promotes DNA breaks, lipid peroxidation and protein oxidation [36] . Further work has revealed that NO also mediates apoptotic cell death; however, the mechanism is not well understood [37] .
GAPDH had received particular attention as one of the major targets of NO in cells after the discovery of NO-induced ADP ribosylation of GAPDH, inhibiting its glycolytic activity [38, 39] . Further work revealed that it was S-nitrosylation facilitated NAD covalent linkage (not ADP-ribose) [40, 41] . Although inhibition of GAPDH glycolytic activity could be a potential mechanism of NO-induced cell death [42] , the field stalled without a causal link between cell death and NOdependent energy depletion [43] .
S-nitrosylation has been established by Stamler and colleagues [44] as a major signaling mechanism for NO. It occurs at cysteine residues of many proteins in the presence of NO, and has been shown to affect protein-protein interactions [45, 46] . S-nitrosylation of GAPDH in wild-type mice, but not in neuronal NO synthase (nNOS) knockout mice, establishes a physiological relevance for this modification [47] , however, the significance of S-nitrosylated GAPDH at basal levels is unknown. Poly(ADP-ribose) polymerase (PARP) is a downstream mediator of nNOS and NO [48, 49] . PARP, once over-activated upon stroke and pathological conditions with a massive release of glutamate, contributes to necrotic cell death [48] [49] [50] . The glutamate/nNOS/PARP cascade, however, also plays a role in basal conditions by regulating neuronal energy dynamics [51] . Similarly, Snitrosylated GAPDH may have roles in both basal and pathological conditions.
Nuclear translocation of GAPDH in apoptosis
Chuang and associates [31] initially reported involvement of GAPDH in apoptosis by using cultured cerebellar granule neurons. They found a 38-kDa protein that was overexpressed before age-dependent apoptosis and identified the protein as GAPDH by N-terminal sequencing. Application of antisense oligonucleotides to GAPDH in attempts to knock down expression of GAPDH prevented neuronal cell death, suggesting that a pool of GAPDH might acquire a gain-of-toxic function during cell death. Similar observations were obtained from cerebral cortical culture and cerebellar granule cells with a variety of stress types including cytosine arabinoside (AraC) and reduced concentrations of KCl [22, 32, 33] .
Following these studies, we discovered a general role for GAPDH in multiple models of cell death in cell cultures from diverse tissues, including primary thymocytes, S49 lymphocyte cells, PC12 cells, and cerebral cortical neurons [23] . In thymocytes and S49 cells, overexpression of GAPDH occurs after the addition of dexamethasone (Dex). Antisense oligonucleotides, but not sense, to GAPDH delay the cytotoxicity (Fig.  1A) . Besides the overall overexpression of GAPDH, we discovered a striking translocation of GAPDH to the nucleus which was much larger than its increased overall expression (Fig. 1B) [23] .
Several other groups have also observed nuclear translocation of GAPDH during cell death [18] [19] [20] [21] 24, 25, [27] [28] [29] [30] . Furthermore, they highlighted oxidative stresses such as H 2 O 2 or FeCN [30] , or 1-methyl-4-phenylpyridinium (MPP + ) [27, 28] , as triggers of this nuclear translocation. Saunders [25] reported that GAPDH purified from the nucleus of apoptotic cells is resistant to in vitro SNPinduced NAD labeling, suggesting that GAPDH translocated to the nucleus may have the catalytic cysteine (C150 in rat GAPDH) occupied as a result of a posttranslational modification.
In the nucleus of apoptotic cells, GAPDH is enriched in the fraction that is resistant to DNase/detergent, biochemically similar to the nuclear matrix [23] . GAPDH reportedly binds to PML [52] , a main component of the nuclear bodies that are biochemically enriched in the DNase/detergent resistant nuclear matrix. PML was originally identified as a fused protein with the retinoic acid receptor alpha (RAR alpha) in the t(15;17) translocation specifically associated with acute promyelocytic leukemia (APL).
In contrast to irreversible translocation of GAPDH to the nucleus during cell death, reversible nuclear shuttling of GAPDH has also been reported [15, 53] . In the S-phase of HeLa cells, a pool of GAPDH is particularly enriched in the soluble fractions of the nucleus and functions as a transcriptional co-activator [15] . It is not clear whether DNA repair and replication as described above are carried out by cell cycle-associated, reversibly translocated GAPDH. GAPDH contains a nuclear export signal (NES) that functions in a chromosome region maintenance (CRM)1-dependent manner [54] . In DLD1 and SW620 cell lines, treatment with leptomycin B (LMB), an inhibitor of CRM1-mediated nuclear export, leads to the accumulation of GAPDH in the nucleus. Additionally, CRM1 was found to co-immunoprecipitate with a GAPDH, but not with a GAPDH NES mutant. Another group, however, has reported that GAPDH can be transported from the nucleus in a CRM1 independent manner in NIH3T3 cells after serum starvation [55] .
Molecular mechanism for nuclear translocation of GAPDH in apoptosis
Molecular events underlying the nuclear translocation of GAPDH and related cell death have been elusive, as GAPDH lacks a nuclear localization signal (NLS). Moreover, GAPDH forms a 150-kDa homo-tetramer, which is required for its proapoptotic actions in the nucleus, is too large for passive entry into the nucleus. Therefore, it is postulated that there would be carrier proteins that bind to GAPDH and would be needed to facilitate the translocation of GAPDH to the nucleus by active mechanism(s).
Binding of GAPDH and Siah1
: their bi-directional functions for cytotoxicity [56] Our group hypothesized that a protein interactor(s) of GAPDH may play an active role in translocating GAPDH to the nucleus. The yeast two-hybrid screening pointed to an E3 ubiquitin ligase Siah1, because Siah1 is the only clone that contains a well-conserved NLS in its open reading frame. Exogenously overexpressed Siah1 can translocate GAPDH to the nucleus, but Siah1 with site-directed mutations in the NLS does not, suggesting a role of the NLS in Siah1 in nuclear translocation of GAPDH. In turn, GAPDH stabilizes rapidly turning-over Siah1 in the nucleus. This stabilization of Siah1 protein by GAPDH is due to their direct protein binding, as a mutation at lysine 225 (K225) in GAPDH that abolishes the GAPDH-Siah1 protein binding (Fig. 2) results in no more stabilization of Siah1 protein. Downstream of Siah1, degradation of Siah1's substrates in the nucleus may be responsible for cytotoxicity because deletion of the endogenous NLS sequences and RING finger domain, essential for protein degradation in Siah1, abolishes cytotoxicity. Nuclear GAPDH contributes to cell death mainly by inducing cytotoxic actions of Siah1 as a result of its protein stabilization.
S-nitrosylation of GAPDH as a potential trigger for its binding to Siah1
There are two GAPDH genes in mammalian cells with a variety of pseudogenes [57] . GAPDH2, localized on chromosome 19, is expressed only in spermatogenic cells [58] , while GAPDH, found on chromosome 12, is nearly ubiquitously expressed. To explore a general role for GAPDH in cell death, we focused on the more ubiquitous isoform of GAPDH coded for by the GAPDH gene on chromosome 12.
We considered whether specific molecular alterations of GAPDH trigger the binding of GAPDH to Siah1. Studies with mass spectrometry have clarified that C150 is sulphonated in HEK293 cells during cell death induced by NO donors, such as SNP (Fig. 2) . This observation substantiates the previous report by Saunders et al. [25] that GAPDH purified from the nucleus of apoptotic cells is resistant to in vitro SNP-induced NAD labeling, suggesting that nuclear GAPDH may be modified at C150. Sulphonation of cysteine can arise after S-nitrosylation (-SNO) via hydrolysis to sulphenic acid (-SOH) and sequential oxidation to sulphinic acid (-SO 2 H), and then sulphonic acid (-SO 3 H) (Fig. 3) [44] . Biochemical and cellular experiments have shown that the protein interaction of GAPDH and Siah1 is dramatically augmented when GAPDH is S-nitrosylated. The NO-induced modification at C150 of GAPDH seems to be a specific trigger that leads to GAPDH-Siah1 signaling. Fig. 1 . Nuclear translocation of GAPDH in apoptosis (adopted from Sawa et al. [23] ). (A) The effect of antisense oligonucleotides to GAPDH was tested in dexamethasome (Dex)-induced apoptosis in primary thymocytes. After Dex stimulation (3 μM), cytotoxicity was monitored by a trypan blue exclusion assay. Antisense oligonucleotides to GAPDH protect, with levels increased half of the way to control levels. By contrast, GAPDH sense oligonucleotides have no effects. (B) Biochemical characterization of nuclear GAPDH in Dex-treated S49 cells. (Upper) Before stimulation, GAPDH is mainly in cytosolic and P3 fractions with less in P2 and no staining in the nuclear fraction (N). After Dex stimulation, a substantial amount of GAPDH translocates to the nucleus (N). (Lower) Nuclear GAPDH resists extraction; DNase I treatment or high salt treatment (up to 5M NaCl) fails to elute GAPDH from the nuclear pellet fractions.
NO/GAPDH/Siah1-mediated cell death in various cell cultures [56]
The NO/GAPDH/Siah1 cascade seems to have a role in cell death of a variety of cell cultures, including primary neurons. Neuronal cell death in the brain following glutamate excitotoxicity has been associated with excess production of NO by nNOS, as neurotoxicity is diminished in pure neuronal cultures by inhibition of nNOS [59] . In cerebellar granule neurons, cultures from wild-type, but not from nNOS knockout mice, display augmented interaction of GAPDH and Siah1 after the exposure of the glutamate derivative N-methyl-D-aspartate (NMDA), suggesting that the NO/GAPDH/Siah1 signaling plays a role in excitotoxic neuronal cell death. This is confirmed by the observation that knocking down expression of GAPDH and Siah1 by RNA interference (RNAi) treatment led to decreased neuronal death. Consistent with protective actions by RNAi treatment, antisense oligonucleotides to GAPDH were previously used to prove a causal role of GAPDH in cell death [22, 23] . Conceivably, the effects of RNAi and antisense oligonucleotides imply that newly synthesized GAPDH may have some role in cellular toxicity. GAPDH-Siah1 binding is decreased with an addition of NAD + or glyceraldeyde-3-phosphate (Hara, M.R., Sawa, A., and Snyder, S.H.: unpublished observation), indicating that newly synthesized GAPDH, which may not be bound to its glycolytic substrates, may be more susceptible to binding with Siah1. This issue remains to be clarified.
The NO/GAPDH/Siah1 cascade for neuronal cell death may be triggered by another mechanism. Activation of microglia can induce apoptosis in adjacent neurons [60] , and the involvement of inducible NOS (iNOS) in this process has been reported [61, 62] . In a co-culture of microglial and neuronal cells, stimulation of iNOS in microglia with lipopolysaccharide leads to increased levels of S-nitrosylated GAPDH in neuronal cells. Under this condition, the protein interaction of GAPDH and Siah1 is augmented, which is followed by neuronal cell death (Hara, M.R., Snyder, S.H., and Sawa, A.: unpublished observation).
The study described above [56] has established that GAPDH is a mediator of cell death that is triggered by NO (Fig. 4) . PARP is also a mediator of cell death downstream of excess production of NO. DNA damage by NO leads to overactivation of PARP and results in depletion of NAD + /ATP as well as energy depletion. Thus, NO/PARP signaling mediates necrotic cell death [48] [49] [50] . In contrast, NO/GAPDH/Siah1 pathway utilizes a proteasome-dependent degradation of Siah1's substrates that requires energy, and which results in apoptotic cell death [56] .
p53 is a key player in sensing cellular stress, and is involved not only in cancer formations but also in neurodegenerative conditions [63, 64] . Upon recognition of cell stress, p53 binds to specific DNA sequences to regulate transcription of distinct genes. Siah1b, one of two mouse homologues of human Siah1, has been shown to be a direct transcriptional target of p53 and contains a specific p53 response element within its second intron [65] . Additionally, p53 has been shown to upregulate GAPDH in cerebellar granule neurons upon treatment with AraC [21] . Cumulatively, these findings suggest that, in some context, p53 may function upstream of the GAPDH/Siah1 cascade. Fig. 3 . Cascade from S-nitrosylation to sulphonation. Sulphonation of cysteine can arise after S-nitrosylation (-SNO) via hydrolysis to sulphenic acid (-SOH) and sequential oxidation to sulphinic acid (-SO 2 H), and then sulphonic acid (-SO 3 H). Sulphonation of cysteine can also be produced with sequential modifications with reactive oxygen species (ROS). The GAPDH-Siah1 cascade may be involved in sensing oxidative stress in general, as hydrogen peroxide or peroxynitrite treatment of GAPDH elicits the GAPDH-Siah1 binding, but is less effective than S-nitrosylation [56] . Because reactive oxygen species and NO may interact in protein S-nitrosylation, as reported for superoxide [66] , they may have a synergistic effect on the GAPDH-Siah1 cascade.
GAPDH in neurodegenerative conditions
A pathological role for GAPDH has been suggested in several neurological disorders, but its detailed understanding at the molecular level is still awaited. For example, GAPDH may be implicated in Alzheimer's disease (AD). Immunoreactivity of GAPDH was reported in senile plaques in AD [67] and exposure of cortical neurons to amyloid β peptide causes nuclear accumulation of disulfide-linked GAPDH [68] . Specific mutations in amyloid precursor protein (APP) cause familial forms of AD, and the C-terminal portion of APP binds to GAPDH [34] . These observations, although very interesting, have been taken with some reservation, because GAPDH is a very abundant and sticky molecule. A recent intriguing report indicated that the strongest association of chromosome 12p with late-onset AD occurs inside the GAPDH locus [57] .
A pathological role for GAPDH has also been reported in other neurological conditions. Nuclear accumulation of GAPDH in apoptotic neurons in the penumbra after middle cerebral artery occlusion (MCAO) and reperfusion was recently reported [69] . GAPDH immunoreactivity has been observed in Lewy bodies, the pathological hallmark of Parkinson's disease [70] . In polyglutamine diseases such as Huntington's disease, GAPDH binds to the disease gene products (Huntingtin, etc.) in a polyglutamine tract-dependent manner (Fig. 2) [35, [71] [72] [73] . The significance of these protein bindings has yet to be elucidated. Recent findings have shown, however, that GAPDH immunostaining is increased in brain regions such as the neocortex and caudate putamen/globus pallidus in transgenic mice expressing mutant Huntingtin containing 89 glutamine repeats [74] . GAPDH staining in these regions indicates a translocation of GAPDH to the nucleus, and this increased staining is associated with cell loss.
It remains controversial whether or not GAPDH glycolytic activity in brains and fibroblasts of patients with these neurogenerative diseases is altered [73, [75] [76] [77] . It will be important to explore how the NO/GAPDH/Siah1 cascade is involved in neurodegenerative conditions [56] . The antibody against the specific GAPDH peptide containing sulphonated C150 (sGAPDH) may be a useful tool for exploring this possibility. If the unique staining, especially in the nucleus, is observed with the sGAPDH antibody in brains from patients with AD or other conditions, this will suggest that the NO/ GAPDH/Siah1 cascade may be involved in the diseases. Tanaka et al. [69] presented an antibody which may preferentially detect nuclear GAPDH in the ischemic core and penumbra region after focal ischemia. It would be interesting to compare the staining pattern of this antibody and sGAPDH antibody.
GAPDH as a novel therapeutic target
GAPDH is a multifunctional protein important for general cell maintenance as well as an executor of cell death, thus therapeutic approaches aimed at simple reduction of GAPDH levels may not be effective. Instead, a targeted blockade of the specific pool of GAPDH with a gain of toxic function may be an efficient strategy to block GAPDH-mediated cell death in pathological conditions. In concrete, a strategic block of the GAPDH/Siah1 interaction may be effective in preventing cell death in neurological conditions.
The concept of a pool of GAPDH as a mediator for apoptosis has also been suggested pharmacologically [18, 19, [78] [79] [80] [81] [56] ). NO causes S-nitrosylation of GAPDH at C150. S-nitrosylation of GAPDH augments its binding to Siah1 at K225. NLS of Siah1 mediates nuclear translocation of GAPDH. GAPDH stabilizes Siah1 facilitating its degradation of nuclear proteins, which leads to cell death.
TCH346 bind to GAPDH and prevent the nuclear translocation of GAPDH, which leads to cytoprotective effects [19, 81] . In differentiated PC12 cells, TCH 346 at 0.1 to 1 pico-molar order blocks nuclear translocation and rescues apoptotic cell death induced by trophic withdrawal. TCH 346 is cytoprotective in cerebellar granule neurons with cytosine arabinoside, rat embryonic mesencephalic dopaminergic neurons with MPP+, and PAJU human neuroblastoma cells with rotenone. Administration of (−)-deprenyl was neuroprotective in MCAO models in vivo [82] .
Based on the molecular understanding of the NO/GAPDH/ Siah1 cascade, we may be able to design new therapeutic strategies (Fig. 5) . First, the blockade of NO-stimulated protein binding between GAPDH and Siah1 may be an effective way to prevent cell death from this cascade. Both-deprenyl and TCH346 have been shown to function in this manner [84] . Identification of a negative regulator in the cytoplasm that may compete with Siah1 for GAPDH may also facilitate this strategy. Second, it would be worthwhile exploring the downstream molecules of the cascade in the nucleus. Bowtell and colleagues [83] have published a consensus sequence for Siah's substrates. It will be important to identify nuclear substrate(s) that are degraded at the endpoint of the NO/GAPDH/Siah1 cascade, which has a causal role for cytotoxicity. Modulation of these substrates may be a potential therapeutic strategy against cell death.
Concluding remarks
GAPDH is a classic glycolytic enzyme, but recent studies have highlighted its role as a mediator for cell death. Here we describe the NO/GAPDH/Siah1 cascade for cell death that is initiated by a posttranslational modification of GAPDH by NO, leading to the nuclear translocation of the GAPDH-Siah1 protein complex and cell death. The NO/GAPDH/Siah1 death cascade would contribute to the molecular understanding of a role of GAPDH in neurodegenerative disorders and help to establish novel therapeutic strategies.
